A platinated prodrug leveraging PROTAC technology for targeted protein degradation and enhanced antitumor efficacy
PROTAC–Pt( iv ) represents a new class of dual-action Pt( iv ) prodrugs integrating platinum drugs with PROTAC-mediated protein degradation, exhibiting superior antitumor efficacy compared to conventional Pt( iv ) prodrug and PROTAC alone in vivo .
Authors
- Guangyu Zhu (ORCID: https://orcid.org/0000-0002-4710-7070)
- Jiaqian Xu (ORCID: https://orcid.org/0000-0003-4755-1312)
- Ka-Yan Ng (ORCID: https://orcid.org/0000-0001-5199-8198)
- Wei Fu
- Shu Chen (ORCID: https://orcid.org/0000-0003-3244-299X)
- Xianfeng Chen (ORCID: https://orcid.org/0000-0002-3189-2756)
Institutions
- City University of Hong Kong (HK)
- City University of Hong Kong, Shenzhen Research Institute (CN)
- University of Edinburgh (GB)
Publication Details
- Journal
- Inorganic Chemistry Frontiers
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1039/d5qi00605h
- Citations
- 4
- Primary Topic
- Protein Degradation and Inhibitors
- Type
- article
- Field-Weighted Citation Impact
- 3.22